In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Filmore

Executive Editor

Rochester, NY
David Filmore has been covering the health care sector as a writer and editor for 16 years. He specializes in devices and diagnostics, particularly focusing on the regulatory and reimbursement dynamics that impact a company’s ability to succeed in the marketplace. Originally trained as a scientist, Dave enjoys dissecting technical topics to reach a core understanding. As a writer and editor, he relishes communicating that understanding, important context and key takeaways for practical use by the reader. Dave has led operations or served on the staff of “The Gray Sheet” for more than a decade, and now oversees Regulatory and Policy content for the new Medtech Insight. Previously, he was an editor with the American Chemical Society, producing content for professionals in the pharmaceutical industry and analytical instrumentation space. He has also worked in the pharma industry, and has a degree in chemistry. Dave lives with his wife and two kids in Rochester, NY.
Advertisement
Set Alert for Articles By David Filmore

Latest From David Filmore

About Three Months' Worth Of Carryover Device Fees Remaining, FDA's Gottlieb Says

US FDA has about three months' worth of medical device carryover user-fee funds to burn if the partial federal government shutdown continues, although the agency is still finalizing its shutdown balance sheet, Commissioner Scott Gottlieb says.

FDA Regulation

2018 US Device Approvals: The Year Of De Novos And Digital Health

It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.

Approvals FDA

Device Week, Jan. 11, 2019 – A New Plan From NHS In A Period Of UK Uncertainty

On this week's podcast, Ashley Yeo talks about the "Long Term Plan" published by the UK's National Health Service this week, and the implications of Brexit.

Device Week United Kingdom

Global Device Approvals, Weekly Snapshot: Endovascular Entries

A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker. Terumo and Cook each nabbed US FDA approvals for endovascular devices.

Approvals Research & Development

Into 2019: Digital Leads US Policy Innovations, But Public Medtech Scrutiny Grows

Scott Gottlieb's FDA continues to push out policy reforms and experiments at a rapid pace, with special focus on digital and AI technologies. In parallel, US Medicare officials are more publicly signaling plans to roll out policies for a quicker path to reimbursement for new devices. However, public scrutiny of whether device regulations properly protect patient safety is growing, and it could have an impact. 

United States Market Access

US Regulatory Roundup, 2018: 5 Core Issues That Help Explain The Year In Medtech Policy

Global harmonization, regulatory innovation, rising safety scrutiny, medtech reimbursement hopes and global trade threats were key underlying concepts for the medtech regulatory and policy environment in 2018. Here's a spotlight on those issues and the top 30 articles from last year.

Regulation United States
See All
Advertisement
UsernamePublicRestriction

Register